JP2021514956A5 - - Google Patents

Info

Publication number
JP2021514956A5
JP2021514956A5 JP2020544456A JP2020544456A JP2021514956A5 JP 2021514956 A5 JP2021514956 A5 JP 2021514956A5 JP 2020544456 A JP2020544456 A JP 2020544456A JP 2020544456 A JP2020544456 A JP 2020544456A JP 2021514956 A5 JP2021514956 A5 JP 2021514956A5
Authority
JP
Japan
Prior art keywords
composition according
enzyme
administered
composition
trin
Prior art date
Application number
JP2020544456A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514956A (ja
JPWO2019164703A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/017623 external-priority patent/WO2019164703A1/en
Publication of JP2021514956A publication Critical patent/JP2021514956A/ja
Publication of JP2021514956A5 publication Critical patent/JP2021514956A5/ja
Publication of JPWO2019164703A5 publication Critical patent/JPWO2019164703A5/ja
Priority to JP2023139463A priority Critical patent/JP2023162344A/ja
Pending legal-status Critical Current

Links

JP2020544456A 2018-02-22 2019-02-12 コハク酸セミアルデヒドデヒドロゲナーゼ欠損症(ssadhd)を処置するための組成物および方法 Pending JP2021514956A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023139463A JP2023162344A (ja) 2018-02-22 2023-08-30 コハク酸セミアルデヒドデヒドロゲナーゼ欠損症(ssadhd)を処置するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862634092P 2018-02-22 2018-02-22
US62/634,092 2018-02-22
PCT/US2019/017623 WO2019164703A1 (en) 2018-02-22 2019-02-12 Compositions and methods for treating succinic semialdehyde dehydrogenase deficiency (ssadhd)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023139463A Division JP2023162344A (ja) 2018-02-22 2023-08-30 コハク酸セミアルデヒドデヒドロゲナーゼ欠損症(ssadhd)を処置するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2021514956A JP2021514956A (ja) 2021-06-17
JP2021514956A5 true JP2021514956A5 (https=) 2022-03-31
JPWO2019164703A5 JPWO2019164703A5 (https=) 2022-03-31

Family

ID=67688295

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020544456A Pending JP2021514956A (ja) 2018-02-22 2019-02-12 コハク酸セミアルデヒドデヒドロゲナーゼ欠損症(ssadhd)を処置するための組成物および方法
JP2023139463A Pending JP2023162344A (ja) 2018-02-22 2023-08-30 コハク酸セミアルデヒドデヒドロゲナーゼ欠損症(ssadhd)を処置するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023139463A Pending JP2023162344A (ja) 2018-02-22 2023-08-30 コハク酸セミアルデヒドデヒドロゲナーゼ欠損症(ssadhd)を処置するための組成物および方法

Country Status (6)

Country Link
US (2) US20210008225A1 (https=)
JP (2) JP2021514956A (https=)
KR (1) KR20200140255A (https=)
AU (1) AU2019225729A1 (https=)
CA (1) CA3092035A1 (https=)
WO (1) WO2019164703A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250018061A1 (en) * 2021-12-02 2025-01-16 The Children`S Medical Center Corporation Gene therapy in succinic semialdehyde dehydrogenase deficiency (ssadhd)
CN116478961B (zh) * 2023-04-27 2023-09-15 北京因诺惟康医药科技有限公司 CRISPR/SprCas9基因编辑系统的开发及应用
WO2025042900A1 (en) * 2023-08-21 2025-02-27 Washington State University Messenger rna treatment for succinic semialdehyde dehydrogenase deficiency

Similar Documents

Publication Publication Date Title
Birkmayer et al. Implications of combined treatment with'Madopar'and L-deprenil in Parkinson's disease: a long-term study
US20230070600A1 (en) Combination Therapy for Treating or Preventing Depression or Other Mood Diseases
Singh et al. Harnessing the mTOR pathway for tuberculosis treatment
JP2021514956A5 (https=)
Liu et al. Berberine attenuates depressive-like behaviors by suppressing neuro-inflammation in stressed mice
Gojo et al. The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats
Yu et al. Autophagy: Novel applications of nonsteroidal anti‐inflammatory drugs for primary cancer
Park et al. Understanding metabolic regulation between host and pathogens: new opportunities for the development of improved therapeutic strategies against Mycobacterium tuberculosis infection
Kasirzadeh et al. β‐Sitosterol alters the inflammatory response in CLP rat model of sepsis by modulation of NFκB signaling
Villégier et al. Monoamine oxidase inhibitors allow locomotor and rewarding responses to nicotine
Zorzi et al. A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium
Yang et al. Mangiferin alleviates hypertension induced by hyperuricemia via increasing nitric oxide releases
WO2006037031A3 (en) Formulations and methods for treatment of inflammatory diseases
JP2019511496A5 (https=)
CA2614885C (en) Methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities
Kim Spermidine is protective against kidney ischemia and reperfusion injury through inhibiting DNA nitration and PARP1 activation
Zhang et al. Anti-inflammatory action of HO-1/CO in human bronchial epithelium in response to cationic polypeptide challenge
Mazumdar et al. Potential role of the cardiovascular non-antibiotic (helper compound) amlodipine in the treatment of microbial infections: scope and hope for the future
Chatterjee et al. BET‐ting on Nrf2: How Nrf2 signaling can influence the therapeutic activities of BET protein inhibitors
Sun et al. The role of extracellular vesicles in podocyte autophagy in kidney disease
CN109069467B (zh) 肌生成抑制蛋白拮抗剂的用途、含有它们的组合及其用途
Weir et al. mTOR inhibition: the learning curve in kidney transplantation
Trösch et al. First experience with rapamycin-based immunosuppression to improve kidney function after heart transplantation
Pan et al. Trehalose ameliorates autophagy dysregulation in aged cortex and acts as an exercise mimetic to delay brain aging in elderly mice
US10576076B2 (en) Pharmaceutical combination of everolimus with dactolisib